Lingguizhugan decoction dynamically regulates MAPKs and AKT signaling pathways to retrogress the pathological progression of cardiac hypertrophy to heart failure

被引:17
|
作者
Chen, Yao [1 ]
Li, Lin [1 ,2 ]
Hu, Cunyu [1 ]
Zhao, Xin [1 ,2 ]
Zhang, Peng [1 ]
Chang, Yanxu [1 ,3 ]
Shang, Ye [1 ]
Pang, Yafen [1 ]
Qian, Weiqiang [1 ]
Qiu, Xianzhe [1 ]
Zhang, Hongxia [4 ]
Zhang, Deqin [1 ,3 ]
Zhang, Shukun [5 ]
Li, Yuhong [1 ,2 ,3 ]
机构
[1] Tianjin Univ Tradit Chinese Med, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Minist Educ, Key Lab Pharmacol Tradit Chinese Med Formulae, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China
[3] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China
[4] Tianjin Univ Tradit Chinese Med, Affiliated Hosp 2, 69 Zeng Chan Rd, Tianjin 300250, Peoples R China
[5] Tianjin Nankai Hosp, Inst Acute Abdominal Dis Integrated Tradit Chines, 6 Chang Jiang Rd, Tianjin 300100, Peoples R China
基金
中国国家自然科学基金;
关键词
Lingguizhugan decoction; Heart failure; Cardiac hypertrophy; Pressure overload; AKT-GSK3; beta/mTOR/P70S6K; MAPKs; NITRIC-OXIDE; ACTIVATION; 8-PRENYLNARINGENIN; INACTIVATION; RESTORATION; INHIBITION; PROTECTS; GENES;
D O I
10.1016/j.phymed.2022.153951
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: Heart failure (HF) is a grave health concern, with high morbidity and mortality, calling for the urgent need for new and alternative pharmacotherapies. Lingguizhugan decoction (LD) is a classic Chinese formula clinically used to treat HF. However, the underlying mechanisms involved are not fully elucidated. Purpose: Based on that, this study aims to investigate the effects and underlying mechanisms of LD on HF. Methods: After confirming the therapeutic benefits of LD in transverse aortic constriction (TAC)-induced HF mice, network pharmacology and transcriptomic analyzes were utilized to predict the potential molecular targets and pathways of LD treatment in failing hearts, which were evaluated at 3 and 9 w after TAC. UHPLC-QE-MS analysis was utilized to detect bioactive ingredients from LD and plasma of LD-treated rats. Results: Our results showed that LD markedly alleviated cardiac dysfunction via down-regulating CH-related genes and proteins expression in TAC mice. Significantly, cardiac hypertrophy signaling, including AKT and MAPKs signaling pathways, were identified, suggesting the pathways as likely regulatory targets for LD treatment. LD inhibited p38 and ERK phosphorylated expression levels, with the latter effect likely dependent on regulation of AMPK. Interestingly, LD exerted a dual modulatory role in the AKT-GSK3 beta/mTOR/P70S6K signaling pathway's regulation, which was characterized by stimulatory activity at 3 w and inhibitory effects at 9 w. Finally, 15 bioactive compounds detected from plasma were predicted as the potential regulators of the AKT-GSK3 beta/mTOR and MAPKs signaling pathways. Conclusion: Our study shows LD's therapeutic efficacy in failing hearts, signifies LD as HF medication that acts dynamically by balancing AKT-GSK3 beta/mTOR/P70S6K and MAPKs pathways, and reveals possible bioactive compounds responsible for LD effects on HF.
引用
收藏
页数:17
相关论文
共 11 条
  • [1] Arctiin protects against cardiac hypertrophy through inhibiting MAPKs and AKT signaling pathways
    Li, Jing
    Yuan, Yu-Pei
    Xu, Si-Chi
    Zhang, Ning
    Xu, Chun-Ru
    Wan, Chun-Xia
    Ren, Jie
    Zeng, Xiao-Feng
    Tang, Qi-Zhu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 135 (03) : 97 - 104
  • [2] Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets
    Tham, Yow Keat
    Bernardo, Bianca C.
    Ooi, Jenny Y. Y.
    Weeks, Kate L.
    McMullen, Julie R.
    ARCHIVES OF TOXICOLOGY, 2015, 89 (09) : 1401 - 1438
  • [3] Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets
    Yow Keat Tham
    Bianca C. Bernardo
    Jenny Y. Y. Ooi
    Kate L. Weeks
    Julie R. McMullen
    Archives of Toxicology, 2015, 89 : 1401 - 1438
  • [4] CpG-ODN Attenuates Pathological Cardiac Hypertrophy and Heart Failure by Activation of PI3Kα-Akt Signaling
    Yang, Liang
    Cai, Xiangyu
    Liu, Jie
    Jia, Zhe
    Jiao, Jinjin
    Zhang, Jincai
    Li, Changlin
    Li, Jing
    Tang, Xiang D.
    PLOS ONE, 2013, 8 (04):
  • [5] Conditional activation of Akt in the heart provides mechanistic insights into progression from compensated cardiac hypertrophy to heart failure
    Shiojima, I
    Sato, K
    Ito, M
    Liao, R
    Colucci, WS
    Walsh, K
    CIRCULATION, 2003, 108 (17) : 14 - 14
  • [6] KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression
    Tang, Xinmiao
    Wang, Peiwei
    Zhang, Rongli
    Watanabe, Ippei
    Chang, Eugene
    Vinayachandran, Vinesh
    Nayak, Lalitha
    Lapping, Stephanie
    Liao, Sarah
    Madera, Annmarie
    Sweet, David R.
    Luo, Jiemeng
    Fei, Jinsong
    Jeong, Hyun-Woo
    Adams, Ralf H.
    Zhang, Teng
    Liao, Xudong
    Jain, Mukesh K.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (03):
  • [7] Wnt-signaling plays a critical role in cardiac hypertrophy and heart failure progression in mice
    Benkner, A.
    Ruedebusch, J.
    Poesch, A.
    Doerr, M.
    Voelker, U.
    Felix, S. B.
    Grube, K.
    EUROPEAN HEART JOURNAL, 2015, 36 : 833 - 834
  • [8] Allicin attenuates pathological cardiac hypertrophy by inhibiting autophagy via activation of PI3K/Akt/mTOR and MAPK/ERK/mTOR signaling pathways
    Ba Lina
    Gao Jingquan
    Chen Yunping
    Qi Hanping
    Dong Chonghui
    Pan Hao
    Zhang Qianhui
    Shi Pilong
    Song Chao
    Guan Xueying
    Cao Yonggang
    Sun Hongli
    PHYTOMEDICINE, 2019, 58
  • [9] Molecular mediators, characterization of signaling pathways with descriptions of cellular distinctions in pathophysiology of cardiac hypertrophy and molecular changes underlying a transition to heart failure
    Melaku, Leta Shiferaw
    Desalegn, Tewodros
    INTERNATIONAL JOURNAL OF HEALTH AND ALLIED SCIENCES, 2019, 8 (01): : 1 - 24
  • [10] Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling
    Benard, Ludovic
    Oh, Jae Gyun
    Cacheux, Marine
    Lee, Ahyoung
    Nonnenmacher, Mathieu
    Matasic, Daniel S.
    Kohlbrenner, Erik
    Kho, Changwon
    Pavoine, Catherine
    Hajjar, Roger J.
    Hulot, Jean-Sebastien
    CIRCULATION, 2016, 133 (15) : 1458 - 1471